recombinant human somatotropin
Pre-clinicalUNKNOWN 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pseudohypoparathyroidism
Conditions
Pseudohypoparathyroidism, Growth Hormone Deficiency, Dwarfism
Trial Timeline
— → —
NCT ID
NCT00497484About recombinant human somatotropin
recombinant human somatotropin is a pre-clinical stage product being developed by Eli Lilly for Pseudohypoparathyroidism. The current trial status is unknown. This product is registered under clinical trial identifier NCT00497484. Target conditions include Pseudohypoparathyroidism, Growth Hormone Deficiency, Dwarfism.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00497484 | Pre-clinical | UNKNOWN |